TORONTO, ON–(Marketwired – July 12, 2016) –
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES
PharmaCan Capital Corp. (“PharmaCan” or the “Company”) (TSX VENTURE: MJN) is pleased to announce that Mr. Jason Adler will be joining the board of directors.
Jason looks to make an immediate impact on PharmaCan, offering his business experience and guidance to assist management with strategic, operational, and financial decisions.
“I’ve been fortunate enough to play an active role in many successful business ventures; but the chance to be part of a company that has the potential to help people who are suffering right now and really do some good in the world, while offering great value to shareholders, is so rare and incredibly fulfilling.” said Jason. “With its new management team and broader vision, PharmaCan is set to become the industry leader, not only in the Canadian cannabis market, but globally. I am very excited to help the Company achieve its goals and to be a part of its very bright future.”
“I am thrilled to welcome Jason to our board of directors,” said Michael Gorenstein, CEO of PharmaCan. “I know from working with Jason in the past that his wisdom, leadership, and data driven approach will take PharmaCan to new heights.”
Jason is the CEO and Managing Member of Alphabet Ventures, LLC, a captive investment vehicle operating in a wide range of domains including growth equity, established companies with growth perspective, and creative debt vehicles. Prior to Alphabet Ventures Jason was the founder and CEO of Alphabet Management, LLC, a New York based volatility fund, that focused on identifying mispriced assets across various industries, asset classes and geographies. Jason also founded Geronimo, LLC, an AMEX member broker dealer that made markets in equity options, and he began his career as a market maker at G&D Trading, an AMEX member market maker. Jason received his B.A. from the University of Rhode Island.
About PharmaCan Capital Corp.
PharmaCan is a company in the business of investing in companies licensed to produce medical marihuana pursuant to Canada’s MMPR.
Forward Looking Statements
This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, including the Company’s ability to implement its business development strategy. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. All forward-looking information contained in this news release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, PharmaCan disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information was obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investor & Media Relations
Michael Krestell
PharmaCan Capital Corp.
Phone: (416) 603-7381 EXT #236
Email: [email protected]
